Tri Chemical Laboratories (4369) Q3 2026 earnings summary

Executive summary

• Net sales for the nine months ended October 31, 2025, rose 37.4% year-over-year to ¥18,010 million, with operating profit up 30.2% to ¥4,561 million and profit attributable to owners of parent up 24.6% to ¥4,021 million.

• Comprehensive income increased 27.1% year-over-year to ¥4,069 million.

Financial highlights

• Gross profit for the period was ¥6,860 million, up from ¥5,472 million in the prior year.

• Ordinary profit increased 25.4% year-over-year to ¥5,458 million.

• Basic earnings per share rose to ¥123.76 from ¥99.29 year-over-year.

• Total assets increased to ¥42,191 million from ¥36,944 million as of January 31, 2025.

• Net assets grew to ¥34,519 million, with an equity-to-asset ratio of 81.8%.

Outlook and guidance

• Full-year net sales forecast is ¥23,000 million, up 21.7% year-over-year.

• Operating profit is projected at ¥5,500 million, up 4.6% year-over-year.

• Profit attributable to owners of parent is forecast at ¥4,800 million, down 3.3% year-over-year.

• Basic earnings per share for the full year is expected to be ¥147.71.

• Annual dividend forecast is ¥35.00 per share.